Advertisement

Picture EBD Group Digital Medicine & Medtech Showcase 2021 at BTS2021 651x81
Document › Details

Mondobiotech Holding AG. (5/2/12). "Press Release: Mondobiotech Holding AG Announces Changes in the Composition of the Board of Directors". Stans.

Organisations Organisation Mondobiotech Holding AG
  Today Relief Therapeutics Holding AG (SIX: RLF, OTCQB: RLFTF)
  Group Relief Therapeutics (Group)
  Organisation 2 BioPharma Invest AG
Products Product drug discovery
  Product 2 DRUGS, ORPHAN
  Index term 2 Mondobiotech–BioPharma Invest: investment, 201205 existent BioPharma Invest AG is main shareholder
     


mondoBIOTECH holding AG (SIX: RARE) announces that Prince Michael von und zu Liechtenstein and Graf Francis von Seilern-Anspang, both members of the Board of Directors (the "Board") of mondoBIOTECH holding AG (the "Company"), today informed the Board that, other than announced in the invitation to the Company's ordinary shareholders meeting published by press release of 5th April 2012, they will not stand for re-election to the Board at the Company's ordinary shareholders meeting of 3rd May 2012.

Prince Michael von und zu Liechtenstein and Graf Francis von Seilern-Anspang who have been on the Board since 2007 and 2010, respectively, are representatives of the Company's main shareholder, BioPharma Invest AG. They have come to the conclusion that it is in the best interest of the Company and of its shareholders to have, in the current situation, a fully independent Board.

Prince Michael von und zu Liechtenstein furthermore confirmed that BioPharma Invest AG remains strongly committed with the Company. In addition to fulfilling its obligations towards the Company in connection with the subordinated and unsecured loan facility granted to mondoBIOTECH holding AG on 14th November 2011, BioPharma Invest AG is willing to further support the Company by making available shares in the Company to facilitate the Company's efforts for additional funding and/or corporate transactions.

The other current members of the Board, Robert Edward Patterson, Prof. Michael Alan Keller, Marc Häsler, Vincenzo Romano and Ruggero Gramatica confirmed that they will stand for re-election as foreseen.

It is not envisaged to propose other candidates at the Company's ordinary shareholders meeting scheduled for 3rd May 2012.


About mondoBIOTECH

mondoBIOTECH holding AG (SIX Swiss Exchange ticker symbol: RARE), an independent Swiss biotech company, discovers drugs for patients suffering from rare diseases through its internally developed Search&Match methodology. In Search&Match mondoBIOTECH's scientists combine their unique knowledge of biologically active human peptides with advanced technology solutions delivering medicinal product candidates for rare diseases to licensing partners.

Furthermore, mondoBIOTECH has built and is expanding a continuously growing Community of high-level physicians and researchers who dedicate their life to rare diseases. This Rare Community is composed of biologists, biochemists, physicians, patients and patient advocacy organizations as well as other persons and organizations who share their experiences, know-how, expertise and skills with mondoBIOTECH to reach out to people who will benefit the most from an effective treatment, the patients.

For further information please contact
mondoBIOTECH holding AG
Maria Teresa D'Antonangelo Buehlmann
Das Kloster
Muergstrasse 18
CH-6370 Stans
Tel.: +41 (0) 840 200 010
Fax: +41 (0) 840 200 011
investor@mondobiotech.com
www.mondobiotech.com

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning mondoBIOTECH holding AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of mondoBIOTECH holding AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. mondoBIOTECH holding AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

   
Record changed: 2017-04-02

Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

More documents for Relief Therapeutics (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioTech Showcase 2021 Whitepaper Presenting 650x80




» top